| Calquence (acalabrutinib) / AstraZeneca |
NCT04930536: Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma |
|
|
| Completed | 4 | 84 | RoW | Acalabrutinib capsule, Calquence® | AstraZeneca | Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma | 05/23 | 05/23 | | |
NCT06651970: Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure |
|
|
| Not yet recruiting | 4 | 60 | Europe, US, RoW | Acalabrutinib, Calquence, Investigator's choice of treatment, Investigator's choice of treatment : i.e venetoclax, Rituximab, Obinutuzumab, Zanubrutinib etc. | AstraZeneca, Fortrea, CALYX Inc., eResearch Technology, Inc., CISCRP Inc. | Chronic Lymphocytic Leukaemia, Heart Failure | 08/30 | 10/30 | | |
| Active, not recruiting | 3 | 535 | Europe, Canada, US, RoW | Acalabrutinib, ACP-196 (Calquence), Obinutuzumab, GAZYVA / GAZYVARO, Chlorambucil, LEUKERAN | Acerta Pharma BV | Chronic Lymphocytic Leukemia | 02/19 | 09/25 | | |
|
|
|
|
|
2018-002443-28: This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with already marketed drugs called Venetoclax and Obinutzumab in comparison to chemotherapy that is already in wide use for treatment of patients who have chronic lymphocytic leukemia and who have never been treated before. |
|
|
| Not yet recruiting | 3 | 780 | Europe, RoW | acalabrutinib, ACP-196, Capsule, hard, Concentrate for solution for infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Film-coated tablet, Powder for concentrate for solution for infusion, Gazyvaro, MABTHERA, Venclyxto | Acerta Pharma B.V., ACERTA PHARMA BV, AstraZeneca, Acerta Pharma B.V., AstraZeneca AB, ASTRAZENECA AB, Acerta BV | Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation, Previously untreated low-risk blood cancer, Diseases [C] - Cancer [C04] | | | | |
2019-001804-39: Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia Estudio para investigar el uso de acalabrutinib en el tratamiento de pacientes con Leucemia Linfocítica Crónica |
|
|
| Not yet recruiting | 3 | 130 | Europe | Acalabrutinib, ACP-196, Capsule, hard | Fundación PETHEMA, AstraZeneca | Early Stage CLL With High Risk of Early Disease Progression LLC en estadio temprano con alto riesgo de progresión temprana de la enfermedad, Chronic lymphocytic leukemia Leucemia Linfocítica Crónica, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Active, not recruiting | 3 | 533 | Europe, US, RoW | Acalabrutinib, ACP-196, Ibrutinib | Acerta Pharma BV | Chronic Lymphocytic Leukemia | 09/20 | 01/28 | | |
|
|
|
2020-004360-26: Comparison of a fixed-duration treatment of acalabrutinib, venetoclax and obinutuzumab to a treatment of venetoclax and obinutuzumab in patients with high risk chronic lymphocytic leukemia Vergleich einer befristeten Therapie mit Acalabrutinib, Venetoclax und Obinutuzumab mit der Therapie von Venetoclax und Obinutuzumab bei Patienten mit chronischer lymphytischer Leukämie mit hohem Risiko |
|
|
| Not yet recruiting | 3 | 178 | Europe | Acalabrutinib, Obinutuzumab, Venetoclax, RO5072759, Capsule, hard, Concentrate for solution for infusion, Film-coated tablet, Calquence, Gazyvaro®, Venclyxto | German CLL Study Group (University of Cologne), AstraZeneca | Patients with previously untreated chronic lymphocytic leukemia with treatment requiring disease and at least one out of three risk factors (17p-deletion, TP53 mutation or Complex karyotype)., Patients with chronic lymphocytic leukaemia (blood cancer) in need of firstline treatment and at least one out of three risk factors., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 310 | Europe, Canada, US, RoW | Acalabrutinib (ACP-196), Rituximab, Idelalisib, Bendamustine | Acerta Pharma BV | Chronic Lymphocytic Leukemia | 09/21 | 10/27 | | |
|
|
|
|
BELLWAVE-011, NCT06136559: A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/) |
|
|
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Nemtabrutinib, MK-1026, ARQ 531, Ibrutinib, Acalabrutinib | Merck Sharp & Dohme LLC | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 09/32 | 09/32 | | |
NCT06319456: A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. |
|
|
| Recruiting | 3 | 344 | RoW | Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine, Cyclophosphamide，CTX, Rituximab, Chlorambucil | Ascentage Pharma Group Inc. | CLL/SLL | 08/27 | 08/28 | | |
D822BC00001, NCT04075292: Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 3 | 155 | RoW | Acalabrutinib, Rituximab, Chlorambucil | AstraZeneca | Untreated Chronic Lymphocytic Leukemia | 11/24 | 11/24 | | |
|
|
|
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) |
|
|
| Recruiting | 3 | 120 | US, RoW | Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab | AbbVie | Chronic Lymphocytic Leukemia | 10/26 | 10/26 | | |
NCT04178798: Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 3 | 22 | Europe | Acalabrutinib 100 MG Oral Capsule | PETHEMA Foundation | Chronic Lymphocytic Leukemia- Binet Staging System | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 552 | Europe, Canada, US, RoW | Acalabrutinib, ACP-196 | AstraZeneca, Parexel | Chronic Lymphocytic Leukemia | 09/25 | 09/25 | | |
CLL16, NCT05197192 / 2020-004360-26: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL |
|
|
| Recruiting | 3 | 650 | Europe | Obinutuzumab, Gazyva, Gazyvaro, Venetoclax, Venclexta, Venclyxto, Acalabrutinib, Calquence | German CLL Study Group, AstraZeneca | Chronic Lymphocytic Leukemia | 05/26 | 02/27 | | |
NCT05211856: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL |
|
|
| Recruiting | 3 | 780 | Europe, Canada, US, RoW | Acalabrutinib, Calquence (acalabrutinib), Venetoclax, Venclyxto, Venclexta, Chemoimmunotherapy, Obinutuzumab, Gazyva, Gazyvaro | AstraZeneca | Chronic Lymphocytic Leukemia | 01/27 | 01/27 | | |
AMPLIFY, NCT03836261: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL |
|
|
| Active, not recruiting | 3 | 984 | Europe, Canada, US, RoW | Acalabrutinib, Calquence (acalabrutinib), Venetoclax, Venclyxto, Venclexta, Chemoimmunotherapy, Obinutuzumab, Gazyva, Gazyvaro | Acerta Pharma BV, AstraZeneca | Chronic Lymphocytic Leukemia | 01/27 | 01/27 | | |
|
|
|
|
MAJIC, NCT05057494 / 2021-003936-10: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
|
| Active, not recruiting | 3 | 607 | Europe, US, RoW | Acalabrutinib, Venetoclax, Obinutuzumab | AstraZeneca | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 07/27 | 04/29 | | |
2019-000270-29: The trial will investigate whether three months of treatment with a combination of two types of medication given as tablets can reduce the risk of infection and the need for regular CLL treatment when given to newly diagnosed CLL patients. |
|
|
| Not yet recruiting | 2/3 | 212 | Europe | Venetoclax 10 mg, Venetoclax 50 mg, Venetoclax 100 mg, Accalabrutinib, ACP-196, Tablet, Capsule, Venclyxto | Rigshopitalet/Copenhagen University Hospital, Novo Nordisk Foundation, Pharma Acerta, Abbvie | Chronic Lymphocytic Leukemia, Chronic cancer of white blood cells and bone marrow, Diseases [C] - Cancer [C04] | | | | |
2018-003465-33: Acalabrutinib in CLL and MCL patients subjected to allogeneic hematopoietic stem cell transplantation (alloSCT). Zastosowanie akalabrutynibu u chorych z przewlekłą białaczką limfocytową lub chłoniakiem z komórek płaszcza poddanych allogenicznemu przeszczepieniu komórek macierzystych. |
|
|
| Not yet recruiting | 2 | 40 | Europe | acalabrutinib, ACP-196, Capsule, hard, Calquence | Polish Lymphoma Research Group - PLRG, Acerta Pharma, LLC | Mantle Cell Lymmphoma (MCL)Chronic Lymphocytic Leukaemia (CLL) Przewlekła białaczka limfocytowa (CLL)Chłoniak z komórek płaszcza (MCL), Mantle Cell Lymmphoma (MCL)Chronic Lymphocytic Leukaemia (CLL) Przewlekła białaczka limfocytowa (CLL)Chłoniak z komórek płaszcza (MCL), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
15-H-0016, NCT02337829: Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL |
|
|
| Active, not recruiting | 2 | 48 | US | Acalabrutinib (Arm A), ACP-196, Acalabrutinib (Arm B) | Acerta Pharma BV, National Institutes of Health (NIH) | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/20 | 04/26 | | |
|
|
2019-004337-17: Behandeling van chronische lymfatische leukemie met venetoclax en acalabrutinib bij terugkeer van de ziekte na eerdere behandeling met venetoclax in combinatie met immuuntherapie Retreatment of CLL with venetoclax and acalabrutinib after relapse after first line venetoclax treatment combined with immunotherapy for chronic lymphocytic leukemia (CLL or SLL) |
|
|
| Ongoing | 2 | 60 | Europe | venetoclax 10 mg, venetoclax 50 mg, venetoclax 100 mg, Acalabrutnib, Tablet, Capsule, hard, Venclyxto | HOVON Foundation, AbbVie B.V., AstraZeneca BV | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 60 | Europe, US, RoW | ACP-196 (acalabrutinib), Acalabrutinib | Acerta Pharma BV | Chronic Lymphocytic Leukemia | 10/20 | 09/26 | | |
|
| Completed | 2 | 46 | Europe | Bendamustine, Obinutuzumab, GA101, Gazyvaro, Acalabrutinib, ACP-196, Calquence, Venetoclax, ABT-199, Venclyxto | German CLL Study Group | Chronic Lymphoid Leukemia | 02/21 | 09/23 | | |
2020-006081-36: STop and restart Acalabrutinib In fRail patients with previously untreated CLL (STAIR) Arrêt et reprise de l’Acalabrutinib chez les patients fragiles présentant une leucémie lymphoîde chronique non précédemment traitée (STAIR) |
|
|
| Not yet recruiting | 2 | 160 | Europe | ACALABRUTINIB, Capsule, CALQUENCE | FILO, ASTRAZENECA | Chronic lymphoid leukemia leucémie lymphoide chronique, fRail patients with previously untreated CLL Patients fragiles atteints d'une LLC non précédemment traitée, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2020-002142-17: Evaluation of a treatment with acalabrutinib in very old (≥80 years) or frail patients with chronic lymphocytic leukemia Beurteilung einer Therapie mit Acalabrutinib bei sehr alten (≥80 Jahre) oder gebrechlichen Patienten mit chronischer lymphatischer Leukämie |
|
|
| Not yet recruiting | 2 | 53 | Europe | Acalabrutinib/ ACP-196, Capsule, hard + tablet, Calquence | University of Cologne, AstraZeneca | Patients with CLL requiring treatment, Patients with chronic lymphocytic leukaemia in need of treatment, Diseases [C] - Cancer [C04] | | | | |
CLL-Frail, NCT04883749: Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL |
|
|
| Active, not recruiting | 2 | 53 | Europe | Acalabrutinib, Calquence, ACP-196 | German CLL Study Group | Chronic Lymphoid Leukemia | 07/23 | 12/24 | | |
NCT04657094: Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 2 | 4 | US | Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence | City of Hope Medical Center, National Cancer Institute (NCI) | Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia | 04/23 | 12/24 | | |
NCT03788291: Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma |
|
|
| Completed | 2 | 39 | US | Acalabrutinib, Rituximab | University of Rochester | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 05/23 | 05/23 | | |
NCT03580928: Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL |
|
|
| Active, not recruiting | 2 | 72 | US | Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence | Dana-Farber Cancer Institute, AstraZeneca, Genentech, Inc., National Institutes of Health (NIH), National Cancer Institute (NCI) | Chronic Lymphocytic Leukemia (CLL) | 04/24 | 12/27 | | |
|
ACALLO, NCT04716075: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) |
|
|
| Active, not recruiting | 2 | 25 | Europe | Acalabrutinib 2x100 MG Oral Capsule + alloSCT | Polish Lymphoma Research Group, AstraZeneca | Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma, Adverse Event, Response Rate | 06/24 | 09/24 | | |
STAIR, NCT04963946: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia |
|
|
| Recruiting | 2 | 160 | Europe | Stop ACA, ACA Continuation | French Innovative Leukemia Organisation | Untreated Chronic Lymphocytic Leukemia | 01/26 | 08/28 | | |
NCT04505254: Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia |
|
|
| Recruiting | 2 | 60 | US | Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/25 | 06/25 | | |
NCT05388006: Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 30 | US | Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | Mayo Clinic | Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma | 11/24 | 11/25 | | |
NCT05336812: Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia |
|
|
| Recruiting | 2 | 52 | US | Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | Ohio State University Comprehensive Cancer Center | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 12/25 | | |
NCT04624633: Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL |
|
|
| Active, not recruiting | 2 | 60 | US | Acalabrutinib, Calquence, Umbralisib, RP5264, Ublituximab, LFB-R603 | Jennifer R. Brown, MD, PhD, AstraZeneca, TG Therapeutics, Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | 12/26 | 01/30 | | |
Benefit VA, NCT06520098: A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Not yet recruiting | 2 | 100 | US | Venetoclax, VENCLEXTA, Ibrutinib, Acalabrutinib, Zanubrutinib, IMBRUVICA, CALQUENCE, BRUKINSA | VA Office of Research and Development | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/30 | 12/30 | | |
NCT04722172: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL |
|
|
| Active, not recruiting | 2 | 55 | US | Acalabrutinib, Obinutuzumab | Memorial Sloan Kettering Cancer Center, AstraZeneca, Genentech, Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 02/25 | 02/25 | | |
NCT04560322: Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL |
|
|
| Recruiting | 2 | 40 | US | Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence | Massachusetts General Hospital, Genentech, Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 03/25 | 03/25 | | |
NCT03516617: Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 120 | US | Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Laboratory Biomarker Analysis, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Quality-of-Life Assessment, Quality of Life Assessment | Mayo Clinic, National Cancer Institute (NCI) | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 03/25 | 03/26 | | |
| Recruiting | 2 | 90 | US | Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Acalabrutinib | M.D. Anderson Cancer Center | Chronic Lymphocytic Leukemia | 06/25 | 06/25 | | |
BGB-3111-215 , NCT04116437: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment |
|
|
| Recruiting | 2 | 90 | US | Zanubrutinib, BGB-3111, BRUKINSA | BeiGene | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia | 10/25 | 10/25 | | |
NCT04169737: Acalabrutinib and Venetoclax with or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 168 | US | Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma | 07/26 | 07/26 | | |
NCT04941716: Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 20 | US | Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | Fred Hutchinson Cancer Center, AstraZeneca | Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma | 08/27 | 08/31 | | |
NCT04523428: REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) |
|
|
| Recruiting | 2 | 60 | Europe | Venetoclax/Acalabrutinib, Venclexta, Venclyxto | Stichting Hemato-Oncologie voor Volwassenen Nederland | CLL/SLL | 12/28 | 12/32 | | |
NCT04502394: Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL |
|
|
| Recruiting | 1b/2 | 84 | Europe, US, RoW | KRT-232, acalabrutinib, ACP-196 | Kartos Therapeutics, Inc. | Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | 10/22 | 03/24 | | |
KEYNOTE145, NCT02362035: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies |
|
|
| Active, not recruiting | 1/2 | 161 | US | Acalabrutinib, ACP-196, Pembrolizumab, KEYTRUDA | Acerta Pharma BV, Merck Sharp & Dohme LLC | Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia | 07/20 | 04/26 | | |
|
ACE-CL-001, NCT02029443 / 2014-000440-15: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia |
|
|
| Active, not recruiting | 1/2 | 306 | Europe, US | Acalabrutinib, ACP-196 | Acerta Pharma BV | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia | 07/21 | 09/27 | | |
|
|
|
|
|
|
|
|
NCT03932331: Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies |
|
|
| Active, not recruiting | 1/2 | 105 | RoW | Acalabrutinib | AstraZeneca | Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia | 12/22 | 12/23 | | |
|
|
|
|
|
2020-002464-31: A study to evaluate the safety and efficacy of KRT-232 in combination with Acalabrutinib in patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia. Vizsgálat az acalabrutinibbel együtt adott KRT-232 biztonságosságának és hatásosságának értékelésére relapszált/refrakter diffúz nagy B-sejtes limfómában vagy relapszált/refrakter krónikus limfocitás leukémiában szenvedő betegeknél |
|
|
| Not yet recruiting | 1/2 | 114 | Europe, RoW | Acalabrutinib, KRT-232, Tablet, Capsule, hard, CALQUENCE | Kartos Therapeutics Inc., Kartos Therapeutics, Inc, Kartos Therapeutics, Inc. | - Relapsed/Refractory (R/R) de novo TP53 ABC (non-GCB) or GCB diffuse large B-cell lymphoma (DLBCL)- R/R TP53 chronic lymphocytic leukemia (CLL) naïve to prior Bruton's tyrosine kinase (BTK) inhibitor- R/R DLBCL with non-germinal center B-cell like(GCB) subtype- R/R DLBCL with double-expressor lymphoma subtype, - Relapsed/Refractory Diffuse Large B-cell Lymphoma- Relapsed/Refractory Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04] | | | | |
NCT03492125: A Study of the Selective PKC-β Inhibitor MS- 553 |
|
|
| Terminated | 1/2 | 63 | US | MS-553, acalabrutinib, venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, obinutuzumab, Gazyva | MingSight Pharmaceuticals, Inc | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma | 11/23 | 11/23 | | |
Soundtrack-E, NCT06564038: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies |
|
|
| Not yet recruiting | 1/2 | 180 | NA | AZD0486, TNB-486, Acalabrutinib, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin | AstraZeneca | Chronic Lymphocytic Leukaemia, Small Lymphocytic Leukaemia, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma | 01/31 | 01/31 | | |
| Active, not recruiting | 1 | 12 | US | acalabrutinib, ACP-196, ACP-319 | Acerta Pharma BV | Chronic Lymphocytic Leukemia | 07/20 | 04/26 | | |
|
ACE-CL-003, NCT02296918: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL |
|
|
| Active, not recruiting | 1 | 69 | US | acalabrutinib, ACP-196, Obinutuzumab, Gazyvaro, Venetoclax, ABT-199, Venclexta, GDC-0199, Rituximab, Rituxan | Acerta Pharma BV | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia | 08/21 | 09/27 | | |
|
|
|
| Active, not recruiting | 1 | 11 | Europe | Ceralasertib, AZD6738, Acalabrutinib, ACP196 | Acerta Pharma BV | Chronic Lymphocytic Leukemia | 09/21 | 08/26 | | |
|
|
NCT05404282: A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) |
|
|
| Active, not recruiting | 1 | 11 | Europe | Ceralasertib, AZD6738, Acalabrutinib, ACP196 | AstraZeneca | Chronic Lymphocytic Leukemia | 09/21 | 06/23 | | |
NCT05943496: Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma |
|
|
| Recruiting | 1 | 25 | US | Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Questionnaire Administration, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574 | OHSU Knight Cancer Institute, Oregon Health and Science University, Incyte Corporation | Chronic Lymphocytic Leukemia | 01/26 | 01/27 | | |
NCT05971251: Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia |
|
|
| Recruiting | 1 | 24 | US | Loncastuximab Tesirine and Acalabrutinib | Mayur Narkhede, ADC Therapeutics S.A. | Chronic Lymphocytic Leukemia | 12/26 | 12/28 | | |
| Recruiting | N/A | 190 | Europe | acalabrutinib, Calquence | AstraZeneca, Yghea | Chronic Lymphocytic Leukemia | 02/30 | 02/30 | | |
REACH, NCT06170671: REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania |
|
|
| Recruiting | N/A | 250 | Europe | Non interventional study | AstraZeneca | Chronic Lymphocytic Leukemia | 09/28 | 09/28 | | |
NCT04938141: MEOI and HRQoL in CLL Patients Treated With BTKis |
|
|
| Active, not recruiting | N/A | 23 | US | | AstraZeneca | Chronic Lymphocytic Leukemia | 09/24 | 09/24 | | |
NCT04872621: Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation |
|
|
| Completed | N/A | 104 | Japan | | AstraZeneca | Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma) | 09/24 | 09/24 | | |
AQUALIS, NCT06548152: QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database |
|
|
| Not yet recruiting | N/A | 120 | NA | | AstraZeneca, Hospitalidee, Hospitalidee has been asserted to be a valid organization name by UHToulouse | Chronic Lymphocytic Leukemia | 12/25 | 12/25 | | |
CICERO, NCT05517265: Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation |
|
|
| Recruiting | N/A | 50 | Europe | Calquence | iOMEDICO AG, AstraZeneca | CLL | 10/25 | 10/25 | | |
| Active, not recruiting | N/A | 90 | RoW | | AstraZeneca | Chronic Lymphocytic Leukemia | 12/25 | 12/25 | | |
| Withdrawn | N/A | 160 | NA | Electrocardiogram, ECG, Echocardiogram, TTE, Cardiac magnetic resonance imaging, Cardiac MRI, Mobile cardiac telemetry, Mobile telemetry, Blood pressure monitoring, Home blood pressure monitoring, Blood draw | Dana-Farber Cancer Institute, AstraZeneca | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 01/26 | 01/28 | | |
EPIC, NCT05557695: Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom |
|
|
| Recruiting | N/A | 350 | Europe | Acalabrutinib, Calquence | AstraZeneca, UKCLL Forum | Chronic Lymphocytic Leukemia, CLL | 04/26 | 04/26 | | |
| Recruiting | N/A | 200 | Europe | | AstraZeneca | Chronic Lymphocytic Leukaemia (CLL) | 10/26 | 10/26 | | |
NCT05665374: Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study |
|
|
| Active, not recruiting | N/A | 67 | Japan | | AstraZeneca | Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma) | 05/26 | 05/26 | | |
NCT05950997: A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL |
|
|
| Recruiting | N/A | 89 | RoW | Acalabrutinib, Obinutuzumab | The First Affiliated Hospital with Nanjing Medical University, AstraZeneca | Chronic Lymphocytic Leukemia | 05/26 | 09/26 | | |
| Active, not recruiting | N/A | 350 | Europe | Non interventional study | AstraZeneca | Chronic Lymphocytic Leukemia | 11/26 | 11/26 | | |
| Active, not recruiting | N/A | 192 | Europe | | AstraZeneca | Chronic Lymphocytic Leukemia | 12/26 | 12/26 | | |
